Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study of NIDO-361 for Patients with Spinal and Bulbar Muscular Atrophy (SBMA)

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a condition known as Spinal and Bulbar Muscular Atrophy (SBMA). SBMA is a rare genetic disorder that affects muscle strength and movement. The trial will test a new treatment called NIDO-361, which is taken as a tablet. The purpose of the study is to see if NIDO-361 can help restore muscle volume and to check its safety when taken once a day by mouth.

Participants in the study will be randomly assigned to receive either the NIDO-361 tablets or placebo tablets. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are unbiased. The trial will last for a period of up to 12 months, during which participants will have regular check-ups to monitor their health and any changes in their muscle condition.

The main focus of the study is to observe changes in muscle volume using MRI scans, which are special imaging tests that provide detailed pictures of the muscles. The study will also track any side effects experienced by participants and assess their overall physical activity and muscle strength through various tests. This research aims to provide valuable information on the potential benefits and safety of NIDO-361 for individuals with SBMA.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the patient will be required to provide signed written informed consent. This is necessary before any study procedures can begin.

  2. Step 2

    Initial assessments

    The patient will undergo initial assessments to confirm eligibility. This includes a six-minute walk test and a whole-body MRI to evaluate muscle condition.

  3. Step 3

    Randomization

    The patient will be randomly assigned to receive either the NIDO-361 tablet or a placebo. This process is double-blind, meaning neither the patient nor the researchers will know which treatment is being administered.

  4. Step 4

    Medication administration

    The patient will take the assigned tablet orally once daily. The duration of this administration will continue throughout the study period.

  5. Step 5

    Regular monitoring

    The patient will be monitored regularly for any changes in muscle volume using MRI scans. Additionally, the patient will be observed for any adverse events or side effects.

  6. Step 6

    Physical activity assessments

    The patient will undergo various physical activity assessments, including the six-minute walk test, grip strength measurement, and timed up and go test, to evaluate changes from baseline.

  7. Step 7

    Study completion

    Upon completion of the study, the patient will undergo final assessments to evaluate the overall effects of the treatment. This includes a final MRI scan and physical activity tests.

Who can join the trial?

10 criteria

  • Must be able to understand and sign the written consent form before any study procedures.
  • Must be a male who can walk on their own.
  • Must be between 18 and 70 years old.
  • Must have a Body Mass Index (BMI) between 18 and 32. BMI is a measure of body fat based on height and weight.
  • Must have a confirmed diagnosis of Spinal and Bulbar Muscular Atrophy (SBMA) through DNA genetic testing.
  • Must be able to complete a six-minute walk test, which measures how far you can walk in six minutes.
  • Must have a score between 25 and 45 on the Spinal and Bulbar Muscular Atrophy Functional Rating Scale (SBMAFRS), which assesses the severity of the condition.
  • Must show evidence of muscle fat replacement on an initial whole-body Magnetic Resonance Imaging (MRI) scan. This means having at least 10% but no more than 50% muscle fat in affected muscles, with specific volume requirements.
  • If using supplements or vitamins, the dosage must have been stable for at least eight weeks before the screening visit.
  • If not sterilized and sexually active with a female partner who can have children, must agree to use adequate contraception during the study and for 90 days after the last dose. Must also agree not to donate sperm during the study and for three months after the last dose.

Who cannot join the trial?

3 criteria

  • Individuals who are not male cannot participate in the study.
  • Individuals who do not have Spinal and Bulbar Muscular Atrophy cannot participate in the study.
  • Individuals who are part of a vulnerable population cannot participate in the study. A vulnerable population includes groups of people who may need special protection, like children or those with certain disabilities.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

NIDO-361 is a medication being studied for its potential to help patients with Spinal and Bulbar Muscular Atrophy (SBMA). The main goal of the trial is to see if NIDO-361 can increase muscle volume in these patients. Additionally, the study aims to assess how safe and tolerable NIDO-361 is when taken as a daily oral medication.

What is already known about the treatment

NIDO-361 – NIDO-361 is administered orally in the form of a daily pill. It is currently being studied in clinical trials, specifically in a Phase 2 trial, to evaluate its effectiveness and safety for patients with Spinal and Bulbar Muscular Atrophy (SBMA). The main therapeutic indication for NIDO-361 is to help restore muscle volume in individuals affected by this condition. At the molecular level, NIDO-361 works by targeting specific pathways that are believed to influence muscle growth and maintenance. It is classified pharmacologically as a treatment for neuromuscular disorders.

Investigated diseases

Spinal and Bulbar Muscular Atrophy – This is a rare genetic disorder that primarily affects males, characterized by progressive muscle weakness and wasting. It is caused by a mutation in the androgen receptor gene, leading to degeneration of motor neurons in the spinal cord and brainstem. Symptoms often begin in adulthood and include difficulty with speech and swallowing, muscle cramps, and tremors. Over time, individuals may experience increased difficulty with movement and coordination. The disease progresses slowly, and symptoms can vary widely among affected individuals.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2023-507128-22-00Protocol codeNIDO-361-002Estimated enrolment54 patientsSponsorNido Biosciences Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.